Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonist ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic function

Behavioural Pharmacology

Volumn 7, Issue 6, 1996, Pages 513-525

  Kirkby, D L ^a,b,c   Jones, D N C ^a,b   Barnes, J C ^b   Higgins, G A ^a,b  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Cell Biology Unit   (United Kingdom)

Author keywords

5 choice serial reaction time task; acetylcholinesterase inhibitors; attention; delayed match to position; E2020 isomers; ondansetron; rat; scopolamine; short term memory; tacrine; thioperamide

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; HISTAMINE H3 RECEPTOR ANTAGONIST; ONDANSETRON; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST; TACRINE; THIOPERAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; BRAIN FUNCTION; CHOLINERGIC SYSTEM; COGNITION; CONTROLLED STUDY; DRUG ANTAGONISM; FOOD; HYPOTHERMIA; INSTRUMENTAL CONDITIONING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MIOSIS; NONHUMAN; RAT; REACTION TIME; REINFORCEMENT; SALIVATION; SHORT TERM MEMORY; SUBCUTANEOUS DRUG ADMINISTRATION; TASK PERFORMANCE; TREMOR;

EID: 0030462894     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Arrang JM, Drutel G and Schwartz JC (1995) Characterization of histamine H3 receptors regulating acetylcholine release in rat entorhinal cortex. British Journal of Pharmacology, 114, 1518-1522.
2. Atack JR, Perry EK, Bonham JR, Candy JM and Perry RH (1986) Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. Journal of Neurochemistry, 47, 263-277.
3. 3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature, 338, 762-763.
4. 3 receptor antagonist, on cognition in rodents and primates. Pharmacology, Biochemistry and Behaviour, 35, 955-962.
5. Bartus RT, Dean RL, Beer, B and Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408-417.
6. Beerman B (1993) Side effects of long acting cholinesterase inhibitors. Acta Neurologica Scandinavica Supplementum, 149, 53-54.
7. Bliss TVP and Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361, 31-39.
8. Carey GJ, Costall B, Domeney AM, Gerrard PA, Jones DNC, Naylor RJ and Tyers MB (1992) Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacology, Biochemistry and Behaviour, 42, 75-83.
9. Carli M, Robbins TW, Evenden JL and Everitt BJ (1983) Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behavioural Brain Research, 9, 361-380.
10. 3 receptor subtypes. British Journal of Pharmacology, 107, 919-923.
11. 3 receptor-mediated modulation of water consumption in the rat. European Journal of Pharmacology, 232, 99-103.
12. 3 receptor antagonist thioperamide to improve short-term memory and reversal learning in the rat. British Journal of Pharmacology, 110, 65P.
13. Crook T and Lakin M (1991) Effects of ondansetron in age-associated memory impairment. In. Biological Psychiatry, Volume 2 (Eds. G Racagni, N Brunello and T Fukuda), pp. 888-890. Elsevier Science Publishers BV.
14. Dawson GD and Iversen SD (1993) The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behavioural Brain Research, 57, 143-153.
15. Deacon RMJ (1991) Pharmacological studies of a rat spatial delayed nonmatch-to-sample task as an animal model of dementia. Drug Development Research, 24, 67-79.
16. Domeney AM, Costall B, Gerrard PA, Jones DNC, Naylor RJ and Tyers MB (1991) The effect of ondansetron on cognitive performance in the marmoset. Pharmacology, Biochemistry and Behaviour, 38, 169-175.
17. Dunne MP and Hartley LR (1985) The effects of scopolamine upon verbal memory: Evidence for an attentional hypothesis. Acta Psychologica, 58, 205-217.
18. Dunnett SB (1985) Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology, 87, 357-363.
19. Etherington R, Mittleman G and Robbins TW (1987) Comparative effects of nucleus basalis and fimbria fornix lesions on delayed matching and alternation tests of memory. Neuroscience Research Communications, 1, 135-143.
20. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH and Dolan-Ureno J (1992) A controlled trial of tacrine in Alzheimer's disease. Journal of the American Medical Association, 258, 2523-2529.
21. Fibiger HC (1991) Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends in Neuroscience, 14, 220-223.
22. Fontana DJ, Daniels SE, Henderson C, Eglen RM and Wong EHF (1995) Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology, 120, 409-417.
23. Food and Drugs Administration US (1991) Tacrine as a treatment for Alzheimer's disease: editor's note. An interim report from the FDA. A response from Summers et al. New England Journal of Medicine, 324, 349-352.
24. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B and Zhao J (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature, 373, 523-527.
25. Hodges H and Fletcher A (1994) 5-HT3 receptor antagonists enhance spatial learning in rats with cholinergic lesions. Journal of Psychopharmacology. 8, Suppl. A42.
26. 3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology, 117, 318-332.
27. Hyman BT, Van Hoessen GW and Damasio AR (1987) Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Annals of Neurology, 22, 37-40.
28. Johansson IM and Nordberg A (1993) Pharmokinetic studies of cholinesterase inhibitors. Acta Neurologica Scandinavica Supplementum, 149, 22-25.
29. 3 receptor ligands lack modulatory influence on acetylcholine release in rat entorhinal cortex. Naunyn-Schmiedeberg's Archives of Pharmacology, 347, 241-247.
30. Jones DNC, Barnes JC, Kirkby DL and Higgins GA (1993) Behavioural and pharmacological performance disruption in a 5-choice serial reaction time task in rats. Journal of Psychopharmacology 7, Suppl. A82.
31. Jones DNC and Higgins GA (1995) Effect of scopolamine on visual attention in rats. Psychopharmacology, 120, 142-149.
32. Kawashima K, Sato A, Yoshiziwa M, Fujii T, Fujimoto K and Suzuki T (1994) Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 350, 523-528.
33. Kirkby DL, Jones DNC and Higgins GA (1995) Influence of prefeeding and scopolamine upon performance in a delayed matching-to-position task. Behavioural Brain Research, 67, 221-227.
34. Knapp MJ, Knopman DS, Soloman PR, Pendlebury WW, Davis CS and Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 985-1024.
35. Lines CR, Preston GC, Dawson CE, Brazell C and Traub M (1991) The effects of pre-treatment with enalapril maleate on scopolamine-induced cognitive deficits in healthy volunteers. Journal of Psychopharmacology, 5, 228-233.
36. 3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. Journal of Neurochemistry, 58, 2334-2337.
37. Molchan SE, Mellow AM, Lawlor BA, Weingartner HJ, Cohen RM, Cohen MR and Sunderland T (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology, 100, 84-89.
38. Moran PM, Higgins LS, Cordell B and Moser PC (1995) Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proceedings of the National Academy of Sciences USA, 92, 5341-5345.
39. Muir JL, Everitt BJ and Robbins TW (1994) AMPA-induced excitotoxic lesions of the basal forbrain: A significant role for the cortical cholinergic system in attentional function. Journal of Neuroscience, 14, 2313-2326.
40. Muir JL, Everitt BJ and Robbins TW (1995) Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology, 118, 82-92.
41. Murray TK, Cross AJ and Green AR (1991) Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats. Psychopharmacology, 105, 134-136.
42. Nakamura S, Yukawa M and Mimori Y (1992) The effects of acetylcholinesterose inhibitors on acetylcholinesterase in senile plaque. Neurobiology of Aging, 13, S124.
43. Nyback H, Hassan M, Junthe and Ahlin A (1993) Clinical experiences and biochemical findings with tacrine (THA). Acta Neurologica Scandinavica Supplementum, 149, 36-38.
44. 3) antagonist on electrophysiological properties of the rat hippocampus. British Journal of Pharmacology, 112, 695-703.
45. Perry EK (1986) The cholinergic hypothesis - ten years on. British Medical Bulletin, 42, 63-69.
46. 3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacology, Biochemistry and Behaviour, 47, 95-99.
47. Poirier J, Delisle M-C, Quirion R, Aubert I, Farlow M, Lahir D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM and Gauthier S (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proceedings of the National Academy of Sciences USA, 92, 12,260-12,264.
48. 3 receptor antagonist GR68755 on a scopolamine induced cognitive deficit in healthy subjects. British Journal of Clinical Pharmacology, 33, 546.
49. Quon D, Wang Y, Catalano R, Scardina JM, Murakami K and Cordell B (1991) Formation of β-amyloid protein deposits in brains of transgenic mice. Nature, 352, 239-241.
50. Rogers SL, Yamanishi Y and Yamatsu K (1991) The pharmacology of piperidine cholinesterase inhibitor. In: Cholinergic Basis for Alzheimer Therapy (Eds R Becker and E Giacobini), pp. 314-320. Birkhauser, Boston.
51. Rossor M and Iversen LL (1986) Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. British Medical Bulletin, 42, 70-74.
52. Sahgal A, Keith AB and Lloyd S (1990) Effects of nicotine, oxotremorine and 9-amino 1,2,3,4-tetrahydroacridine (tacrine) on matching and non-matching to position in rats: no evidence for mnemonic enhancement. Journal of Psychopharmacology, 4, 210-218.
53. Sahakian BJ and Coull JT (1993) Tetrahydroaminoacridine (THA) in Alzheimer's disease: An assessment of attentional and mnemonic function using CANTAB. Acta Neurologica Scandinavica Supplementum, 149, 29-35.
54. Sarter M, Hagan J and Dudchenko P (1992) Behavioural screening for cognition enhancers: from indiscriminate to valid testing: Part II. Psychopharmacology, 107, 461-473.
55. Schneider LS (1993) Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology, 43, Suppl 4, S64-S79.
56. Smith C and Anderton BH (1994) The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process? Neuropathology and Applied Neurobiology, 20, 322-338.
57. Smith CPS, Hunter, AJ and Bennett GW (1994) Effects of (R)-α-methylhistamine and scopolamine on spatial learning in the rat assessed using a water maze. Psychopharmacology, 114, 651-656.
58. 3 receptor antagonism on hippocampal theta rhythm, memory, and LTP inauction in the freely moving rat. Journal of Neuroscience, 15, 2445-2452.
59. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New England Journal of Medicine, 315, 1241-1245.
60. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI and Lewis KW (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 992-998.
61. Wesnes K and Revell A (1984) The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology, 84, 5-11.
62. Wesnes K, Simpson P and Christmas L (1990) The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Journal of Psychopharmacology, 4, 219-232.
63. Whitehouse PJ (1993) Cholinergic therapy in dementia. Acta Neurologica Scandinavica Supplementum, 149, 42-45.
64. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y and Yamatsu K (1990) Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors. In: Basic Clinical and Therapeutic Aspects of Alzheimer's and Parkinson 's Diseases (vol 2) (Eds T Nagatsu, M Yoshida and A Fisher), pp. 409-413. Plenum Press, New York.
65. Yoshida S and Suzuki N (1993) Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. European Journal of Pharmacology, 250, 117-124.
66. Young AB and Penney JB (1994) Neurotransmitter receptors in Alzheimer disease. In: Alzheimer Disease (Eds RD Terry, R Katzman and KL Bick), pp. 293-303. Raven Press, New York.
67. 3 agonist 2-methyl-5-HT reduces postsynaptic potentials in rat CA1 pyramidal neurones of the hippocampus in vitro. Brain Research, 651, 337-341.
68. Zhang JY, Zeise ML and Wang RY (1994) Serotonin3 receptor agonists attenuate glutamate-induced firing in rat hippocampal CA1 pyramidal cells. Neuropharmacology, 33, 483-491.